Trial Profile
Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs HIL 214 (Primary)
- Indications Norovirus infections
- Focus Adverse reactions
- Sponsors Takeda
- 18 Apr 2019 Results evaluating the long-term safety and immunogenicity six and twelve months after initial vaccination published in the Journal of Infectious Diseases
- 28 Jun 2016 Results published in the Journal of Infectious Diseases
- 12 May 2016 No of arms changed from 5 to 3. Also from primary end points, cohort 1 and cohort 2 separation and time frame for the cohort 2 is removed